USA: A new study published in the Journal of Diabetes and Its Complications suggests that tirzepatide, a novel dual ...

Scientists have found a potential solution to reducing our risk of Alzheimer's disease from an unlikely source: phosphodiesterase type 5 inhibitors, drugs for erectile dysfunction.

The study followed over 269,000 participants for five years, and those who were prescribed erectile dysfunction drugs were 18% less likely to develop Alzheimer’s than those who weren’t.

Phosphodiesterase Type 5 Inhibitors in Men With Erectile Dysfunction and the Risk of Alzheimer Disease. Neurology , 2024; 102 (4) DOI: 10.1212/WNL.0000000000209131 Cite This Page : ...

Tirzepatide also significantly reduced the onset of T2D, with only 1.3% of participants in the treatment groups developing T2D compared to 13.3% in the placebo group (hazard ratio = 0.07, P < 0.001).

People are at higher risk for early death and other outcomes when taking both PDE5i, an erectile dysfunction drug, and chest pain medication, a new study has found. CNN values your feedback 1.

A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had prediabetes and obesity or overweight ...

NEW YORK, Feb. 7 (UPI) --Medications that treat erectile dysfunction may be tied to a lower risk of Alzheimer's disease, a new study indicates. The study was published Wednesday in the online ...